The authors describe the relevant clinical pharmacologic characteristics of three broad classes of existing and investigational treatments, with a focus on mechanisms of action, adverse event profiles, pharmacokinetic and pharmacodynamic properties, and known and predicted resistance pathways.
This article reviews landmark studies that have led to U.S. Food and Drug Administration approval of immunotherapy agents alone or in combination with chemotherapy or other immunotherapy drugs to treat advanced non–small cell lung cancer.
This course describes the epidemiology and risk factors for lung cancer. Practical approaches for promoting tobacco cessation, the leading lung cancer prevention strategy, are presented. Guideline recommendations for lung cancer screening are discussed. A patient case is included.
The KRYSTAL-1 trial was the first-in-human study of the oral KRAS G12C inhibitor adagrasib, which confirmed partial responses in some patients with KRAS G12C–mutant non–small cell lung cancer and colorectal cancer.
USPSTF guidelines have been updated to recommend the use of low-dose computed tomography and expand the criteria for lung cancer screening, aiming to reduce mortality (through more early detection) and ameliorate racial disparities in screening. Despite these updates, screening rates remain low.
This site is intended for healthcare professionals in Europe and Japan only.
The selection of ASCO content on this site was made by the ASCO Publication and Education teams. Springer Healthcare selected the experts for interview. All content is made available solely for educational and informational purposes and personal use only.